← The Neuro Experience
The Neuro Experience
This Psychedelic Is Changing Everything Doctors Thought About Depression
00:33:33
Loading summary
Transcript9 lines
- [00:00]
A
There is a substance that's been classified alongside heroin for over 50 years. It's illegal in most of the world. It has no accepted medical use. And I've spent the last several years inside clinical neuroscience research on some of the most complex questions in brain health. When I look at the psilocybin research that has come out of Johns Hopkins, I'm genuinely stunned. I'm going to walk you through exactly what this drug does to your neurons, why it works where antidepressants fail for decades, and where the research is heading right now. It has produced produced results that are making the most credentialed neuroscientists rethink everything they thought they understood about how the brain heals. Section one, the desynchronization event. The brain runs on patterns. Every thought you think, every mood you feel, every habit you repeat, it's a pattern, a network of neurons firing together in a sequence that's been carved out in your brain by repetition. And that's mostly a beautiful thing. Thing. It's how you learn, it's how you remember, it's how you function. But it's also, in certain conditions, the thing that traps you. Let me build the foundation here, because you need to understand one specific network in your brain before the rest of today makes sense. The network is called the default mode network. Neuroscientists call it the dmn. The default mode network was discovered almost by accident in the early 2000s. Researchers noticed that certain regions of the brain, the medial prefrontal cortex, the posterior cingulate cortex, and the angular gyrus, lit up not during tasks, but between tasks. When the participants were lying in the scanner doing nothing. This network was constantly active. They initially called it task negative network because it seemed to turn off whenever someone was doing something demanding. But we now understand that the DMN is not doing nothing. It's doing something deeply important. It is the network responsible for self referential thought, your sense of self, your narrative, your inner monologue. When you replay a conversation from earlier in the day, when you think about what someone said to you last week and what it meant, when you imagine a future version of yourself, that is your default mode network at work. It is the network that makes you your you. And in a healthy brain, the DMN activates and deactivates in a balanced rhythm. It turns on when attention is inward, when you're resting, when you're consolidating memory or planning. It turns off when you need to direct attention outward to a task, a conversation, a problem. The Brain switches between these modes fluidly and the switching itself is a sign of cognitive health. In depression, that balance is gone. The DMN becomes hyperactive and rigid. It fires constantly, it refuses to turn off. The brain gets stuck in a loop of inward self referential thought that becomes increasingly negative and increasingly narrow. This is not a metaphor for what depression feels like. It's the neurological substrate of it. The rumination, the self criticism, the inability to be present. These are not personality traits. They are a network malfunction. SSRIs and SNRIs primarily target serotonin availability. They increase the concentration of serotonin in the synapse and this changes the chemical environment around the neurons. It can reduce the intensity of the depressive loop over time, but it does not fundamentally disrupt the pattern because the network is still there. The grooves in the record are still there. The antidepressant turns down the volume. Sili cybin does something entirely different. Now think about what that means for someone living with depression. Every morning they wake up, the same network fires the same self critical narrative, the same hopeless framing, the same inability to feel pressure or connection. They take their medication, they, they go to therapy, they try to change the thoughts. But the underlying network, which is the hardware, keeps running the same pattern. For many patients this persists for years, for some for decades. Now Psilocybin, the substance we were talking about today, does something to this network that no pharmaceutical we have ever studied does. It does not adjust it, it doesn't modulate it, it, it takes it offline. Published in Nature in 2024, Siegel and colleagues used something called precision functional mapping. They scanned participants across multiple sessions using functional mri, building detailed maps of individual brain connectivity. What they found was that psilocybin produced massive disruptions to the default mode network. And the word massive is theirs. These are careful researchers writing in a peer reviewed journal, and that is the term they chose. The DMN lost its coherence. The rigid synchronization firing pattern. The loop collapsed. And the collapse was not a signal of damage. It was followed by something unexpected. The brain reorganized. Regions that had never communicated with each other before started firing together. The brain opened new channels. New patterns emerged in the space the old ones had left. Dawes and colleagues, published in nature medicine in 2022, added the next layer. They showed that in depressed patients who responded to psilocybin treatment, the changes in DMN connectivity persisted. At the three week follow up, the disruption was not just acute. And something about the brain's connectivity had been durably Shifted. Patients who showed the strongest DMN disruption during dosing were the most likely to have remission of symptoms three weeks later. The disruption was not a side effect, it was a mechanism. Barrett and colleagues, published in NeuroImage in 2020, made the finding I consider most important for understanding why this matters beyond depression. They showed that psilocybin increases something called global brain connectivity, not just within networks, but between networks. Brain regions that normally operate in separate modules started communicating across those boundaries and the brain became more integrated, more flexible, more interconnected. And these are the same markers of healthy cognitive function that we see in brains with strong executive functions, strong creativity, strong emotional regulation. In 2026, a study published in Nature Communications gave us something that has never been done before. Brain imaging data collected on psilocybin naive participants, people who had never used the substance before using ultra high field mri. And this matters because previous imaging studies had a confound. Participants with prior psychedelic experience may already have structurally different brains. And this study removed that confound. The DMN disruption was confirmed in drug naive brains. This is not a user selection effect. It is the pharmacology. So the brain desynchronizes, the old patterns collapse, the default mode network goes offline. But here is the same question the imaging data immediately raises when something is disrupted. When a pattern breaks, what fills the space? What happens at the cellular level while the network is reforming? That is section two. And that is where the story gets extraordinary.
- [08:04]
B
People spend thousands of dollars on skincare. Serums, creams, lasers. But your skin isn't just something that you just put products on. It's one of the earliest indicators of what's happening inside your body. That's why I don't think about skin as a cosmetic issue. I think about it as a biomarker. Things like zinc, vitamin D, inflammation and metabolic health can all influence how your skin looks and feels. You can't see those from the mirror alone. This is why I use Function Health. Because instead of guessing, I can measure more than 160 different biomarkers in one place and understand what's actually happening beneath the surface. Because when you understand your biology, you can make better decisions. Not just for your skin, but for your brain, your energy and your overall health. Check your health the way I do. Function provides 160 plus lab tests for about a dollar a day and member pricing on advanced imaging. Just head to functionhealth.com louisianicola or use code NEURO25 as your access code. A NEURO25 as your gift code to receive a $25 credit.
- [09:05]
A
Section 2 the Rewiring Every antidepressant on the market works by changing the chemical environment around your neurons. SSRIs adjust serotonin levels. SNRIs adjust serotonin and norepinephrine. They work at the synapse, the gap between neurons. But the neurons themselves, the physical structure of your neural connections remain essentially unchanged. Psilocybin does not just change the chemistry, it changes the architecture. Neurons communicate across connection points called synapses. And the structure of those connection points is not fixed. Neurons have branches, dendrites, and on those branches are tiny protrusions called dendritic spines. Think of them as the fingers of your neurons reaching out to make contact with other neurons. The density of those spines, the complexity of that branching, is a direct measure of how richly connected your neural circuits are. The more spines mean more connections, more connections mean mean more capacity for learning, memory, emotional flexibility and cognitive function. This is one of the most important concepts in neuroscience. Plasticity at the cellular level means the physical structure of your synaptic connections is being remodeled. Dendritic spines are being grown, pruned, strengthened or eliminated. And this structural remodeling is what underlies every form of learning and recovery that we know of. So in a healthy brain, you have robust dendritic spines, dense branching, strong connections. In a brain affected by chronic stress, trauma or major depressive disorder, something measurably happens. Dendritic spine density decreases. Cortisol actively suppresses the molecular signals that build and maintain dendritic spines. Under chronic stress, your neurons literally retract and the branches thin, the connections weaken, the brain becomes physically less connected. Now, Xiao and colleagues published a study in neuron in 2021. They administered a single dose of psilocybin to mice and then they used two photon microscopy to observe what happened in to dendritic spines in the prefrontal cortex. What they found was a 10% increase in dendritic spine density. Within 24 hours, the neurons were growing new connections. And at one month post dose, 60% of new spines were still present. And this is not a metaphorical rewiring. This is a physical measurable rewiring in 24 hours from a single dose. The mechanism driving this was identified by Lai and colleagues in cell reports in 2018. Psilocybin activates serotonin 2A receptors, which triggers the release of brain derived neurotrophic factor or bdnf. BDNF is essentially a fertilizer for neurons. It promotes the growth and maintenance of dendritic spines. It supports the survival of existing neurons. It's the molecular signal that says grow, connect, persist. Exercise is one of the most reliable ways to upregulate bdnf. Psilocybin triggers a BDNF release that is structurally similar to what we see in high intensity exercise. But the scale and speed are completely different. The 2024 comprehensive review by the Open foundation confirmed this across molecular, cellular and network levels. And they added one finding that I want to make sure you hear clearly. The affinity of psilocin, the active metabolite of psilocybin for the TRKB receptor, is 300 times higher than the affinity of conventional antidepressants for the same receptor. 300 times. That is not a marginal difference. That is an order of magnitude difference in the strength of the signal telling your neurons to grow new connections. Zao and colleagues, published in the Journal of psychopharmacology in 2024, bridged the gap between the cellular mechanism and the functional outcome. They measured cognitive flexibility before and after psilocybin treatment. Patients who showed the strongest increases in dendritic connectivity or also showed the greatest improvement in cognitive flexibility. The structural rewiring was translating into measurable behavioral change. So we have the desynchronization event, the old patterns dissolved, and we have physical rewiring new structural connections grown at the cellular level within 24 hours. Now, the natural question here is, what does this mean for actual human outcomes? That is Section three.
- [14:22]
B
Magnesium is one of those nutrients that almost everyone's heard of and everyone takes. But only few people really realize that magnesium isn't just one thing. There's multiple forms, and each one supports different functions throughout the body, whether it's relaxation, brain function, or sleep. This is why I use magnesium. Breakthrough from Bio Optimizers. Instead of relying on a single form, it combines seven different forms of magnesium into one formula. And for me, it's become part of my nightly routine because I don't think about magnesium just as sleep. I think about it as a foundational nutrient that supports recovery and my nervous system. Bio Optimizers has spent more than 20 years developing products like this. And it's the kind of formulation practitioners quietly recommend because of its quality and attention to detail. So. So if you want to try this and you're really ready to optimize your overall health, head to bioptimizers.com neuro and use my exclusive code neuro to get 15% off any order. You'll get great discounts, free gifts, and peace of mind of running out again. That's 15% off@bioptimizers.com neuro or just using
- [15:32]
A
my code neuro section 3 the antidepressant showdown 300 million people worldwide take antidepressants every single day and in 2021 a randomized control trial published in the New England Journal of Medicine compared psilocybin head to head against the gold standard SSRI escitalopram in patients with moderate to severe depression. The results were even more complicated and more important than the headlines suggested. The trial was led by Robin Carhart Harris and published in April 2021. 59 patients all diagnosed with moderate to severe depression randomized to either psilocybin two doses spaced three weeks apart with psychological support or six week course of escitalopram. The primary outcome was depression scores on the validated scale called the QIDSSR16. On the primary measure, the difference between the two groups was was not statistically significant. Psilocybin scored better, but the trial was not powered to detect a small difference on that specific measure. That is the finding that got reported as psilocybin no better than antidepressants. The secondary outcomes were remarkable. Response rate the percentage of patients who showed meaningful improvement Psilocybin 70% Escitalopram 48% remission rate Psilocybin 57% Escitalopram 28% more than double the remission rate in 6 weeks with 2 doses. Psilocybin patients showed significant improvements within 1 week of the first dose. Escitalopram patients were still building to therapeutic effect at week six. The six month follow up published in 2024 showed the psilocybin group maintained their improvements significantly better than the escitalopram group. People who had been in remission at six weeks were more likely to still be in remission at six months if they had received psilocybin. Depression is not an acute condition, it's a chronic recurrent illness. What we need is not a better painkiller. We need treatment that changes the underlying system and the six month data suggests psilocybin may be doing exactly that. The side effect comparison is also striking. SSRIs are associated with sexual dysfunction, emotional blunting, weight changes, insomnia and withdrawal effects. In the Imperial trial, the psilocybin group had lower rates of both sexual function and emotional blunting than the escitalopram group. Compass pathways later extended this picture into treatment resistant depression. Patients who had already failed multiple antidepressants still showed statistically significant improvements 2 doses faster onset, better remission rates, better durability. But depression is not the only condition. The data speaks to section four, the addiction breaker. 80%, that is the smoking abstinence rate at six months in the Johns Hopkins pilot on psilocybin assisted smoking cessation, the best pharmacological smoking cessation treatment we currently have produces roughly 35% abstinence at C6 months. This was more than double. Johnson and colleagues at Johns Hopkins enrolled 15 participants who smoked an average of 19 cigarettes a day for 31 years. Those were not light smokers. The average number of previous quit attempts was six. Participants who received two to three psilocybin sessions combined with cognitive behavioural therapy. At six months, 80% were biologically confirmed as abstinent. At 12 months, 67% remained abstinent. And it is not just smoking. Bogenschultz and colleagues published a randomized controlled trial in jama Psychiatry in 2022 in patients with alcohol use disorder. At eight months, the psilocybin group had significantly fewer heavy drinking days. Across tobacco, alcohol and opioids, the directional findings are consistent. And this appears to affect the underlying architecture of addiction itself. What all addictions share is this. They are patterns. Rigid, overlearned neural patterns carved deep into the brain by repetition. The craving circuit, the reward prediction circuit, the habitual behavior loop. These are not character flaws. They are grooves in the record. The default mode network reinforces that story. Every time it fires psilocybin disrupts the network, it breaks the story. The temporary dissolution of the DMN creates what researchers call a window of enhanced plasticity. The rigid patterns suddenly have less structural reinforcement. And the dendritic spine regrowth allows for new patterns to form in the space the disruption created. The therapy matters enormously here. The disruption of the DMN is acute. But what you do with that window determines whether new patterns form to replace the old ones. The therapy and the pharmacology work together.
- [21:22]
B
One thing I've noticed with all of my guy friends is that they spend a lot of time thinking about what they put in their bodies, but not what they put on their bodies. From protein to creatine to omega 3s, none of them think about what is actually going on top of their bodies. Like shampoo, body wash, face wash. That's why I like Based Body Works. It's a men's grooming brand built around clean plant based formulations like no sulfates, no parabens, no endocrine disrupting chemicals. But they still perform. And optimization isn't about making one huge change. It's about making dozens of smarter decisions. So swapping products you use every day is one of the easiest ones that you can do. If the men in your life have been using the same same products forever without thinking twice about what's in them, this is the easiest upgrade that you can make for them. Send them this episode. I'm sure they'll make the upgrade themselves. Based Body Works is clean plant based men's grooming that actually performs. If you want to buy some, use code neuro for 20% off@basedbodyworks.com and they'll give you a free toiletry bag when you buy a set.
- [22:24]
A
Section 5 the Dark side Everything I've told you so far sounds like a miracle drug. And that is exactly the moment when a scientist gets curious. Because every compound that has produced extraordinary results has also produced extraordinary harms when it was misunderstood or misapplied. I'm going to be honest with you about the risks. Not the risks invented by 50 years of drug war propaganda, the real ones. In every clinical study we have discussed today, adverse events are systematically documented. The most common adverse event event is what researchers call a challenging experience. Patients may experience intense anxiety, confusion, fear or psychological distress during the acute phase of the session. The session lasts six to eight hours. In clinical settings with trained therapists present. The challenging experience is managed. Participants are supported through it in supervised settings with appropriate screening and support. The incidence of serious adverse events is very low, but but six to eight hours of acute psychological distress in an unsupported setting is a completely different risk profile. There's also hard contraindications. Every clinical trial excluded patients with a personal or family history of psychosis, schizophrenia or bipolar disorder. Type 1 psilocybin can exasperate or precipitate psychotic episodes in individuals with genetic vulnerability. This is not theoretical, it's actually a documented mechanism. Cardiovascular disease also requires careful screening. Psilocybin produces transient increases in heart rate and blood pressure for healthy adults. These changes are usually manageable for individuals with underlying cardiac conditions. They require medical evaluations. In fact, a 2025 systematic review examining psilocybin alongside antidepressants found that serotonin syndrome was not observed at standard doses. However, SSRIs significantly blunted the therapeutic effect of psilocybin. HPBD hallucinogen persisting perception disorder is rare but real. A small percentage of people develop persisting visual disturbances after psychedelic use. The incidence in clinical trials is very low, but the mechanism is not very understood. In August 2023 Australia became the first country in the world to formally reclassify psilocybin as a controlled medicine for therapeutic use. Psychiatrists can now prescribe it for for treatment resistant depression under supervised conditions. The evidence threshold for clinical use has been crossed in at least one major jurisdiction. What you should take from this section is not that psilocybin is dangerous. The clinical data is clear that in appropriate populations, with appropriate screening and in supervised settings, the risk profile is manageable. What you should take from this section is is that those conditions are not optional. The policy earthquake on April 18, 2026, the President of the United States signed an executive order directing federal agencies to accelerate the review of psychedelic based therapies. One week later the FDA expanded its breakthrough therapy designations for psychedelic compounds. These are not incremental policy moves. This is the federal government acknowledging that the existing regulatory pathway for psychedelic medicine was too slow for the evidence that had been accumulated. Psilocybin is currently a Schedule 1 controlled substance under the Federal Controlled Substances Act. Schedule 1 means no accepted medical use and high potential for abuse. That classification was established in 1970. The evidence base that exists in 2026 is categorically different. We now have precision FMRI data, two photon microscopy phase three randomized control trials, six month durability data, head to head comparisons with SSRIs. The Compass Pathways NDA submission is expected in late 2026. If approved, psychiatrists in the United States could prescribe a standardized pharmacological grade circumstances psilocybin product for treatment resistant depression. Simultaneously, states are moving faster than the federal timeline. Oregon created a licensed psilocybin services framework. Colorado passed Proposition 122. California, Washington and several other states have active discrimination or legislation efforts underway. Australia is currently the most accessible regulated pathway for English speaking patients. Since August 2023, Australian psychiatrists have been able to prescribe psilocybin for treatment resistant depression under the authorized prescriber scheme.
- [27:48]
B
One of the easiest ways to lose performance is to stop eating well when life gets busy, right? Because you skip lunch and then your energy crashes. That is why IQ Bar is always with me at all times. Their bars are built around clean ingredients like plant protein, fiber and nutrients. Nutrients like magnesium and lion's mane without all the added mess like sugars and everything else. The ultimate sampler pack lets you try IQ Protein bars, IQ Mix, hydration sticks and IQ Joe Mushroom coffee. So for me it's just one less decision I have to make during a busy day. And when you're trying to perform at a high level, this is what really matters right now? IQ Bar is offering our special podcast listeners 20 off all IQ Bar products. Plus you'll get free shipping. All you have to do. It's super simple. Get your phone, text neuro to 64000. That is neuro to 64000.
- [28:41]
A
Why this actually works? Here's the question the molecular data alone cannot answer. If psilocybin's effects were purely pharmacological, you would expect the outcomes to be roughly equivalent across settings. But that is not what the data shows. The magnitude of the therapeutic effect is strongly predicted by the quality of the subjective experience itself. And researchers at Johns Hopkins developed a scale called the Mystical Experience Questionnaire. It measures feelings of unity, transcendence, emotional depth, interconnectedness, and the sense of encountering profound insight. Across multiple independent studies. Higher MEQ scores correlate with substantially better clinical outcomes. Patients who report a complete mystical experience are more likely to be in remission at follow up than patients who had a less intense experience. Same drug. The biology is the same, but the subjective experience predicts the outcome. What this tells us is that psilocybin therapy is not simply a pharmacological invention. The pharmacology opens the window. But what determines whether that window produces durable healing appears to be the quality of the experience in itself. Set and setting are not just supportive elements. They may be active ingredients. The Hopkins and Imperial protocols are extremely specific about both. Music playlists are standardized. Room design is intentional. Therapist training is extensive. Preparation sessions and integration sessions are considered part of the treatment itself. The practical implication is significant. A patient taking a pill and going home would almost certainly produce inferior outcomes to the therapeutic model tested in clinical trials. The drug alone is not the treatment. The the drug plus the therapeutic container is the treatment. This is the real frontier of the research, not whether psilocybin works. The evidence for that is now substantial. But how to deliver it at the scale without stripping out the elements? That's what makes it work. Seven sections. Let's bring it all together. Psilocybin produces massive disruption of the default mode network, the brain's rigid self referential pattern system. That disruption is not damage. It is a pharmacologically induced opening in the space that disruption creates. The brain grows new dendritic connections, physically visible, measurable under a microscope within 24 hours. Those new connections create the structural basis for the new patterns to form. In clinical trials, the mechanism produces antidepressant effects that are faster, more durable and associated with higher remission rates than the best SSRI in the world in two doses. It breaks down addiction patterns across multiple substances at rates that outperform conventional pharmacological approaches. The evidence is in the peer reviewed journals. The phase three trials have run. Australia has already reclassified it for clinical use. The United States is moving. It is not for everyone. Psychotic disorder history is a hard exclusion. Cardiovascular risk requires screening. The therapeutic context is not optional. Unsupervised recreational use produces a completely different risk profile from supervised clinical use. But the right patients in the right settings with trained therapists. The data suggests we may have a treatment that does something psychiatry has never truly done before. A treatment that opens the brain's own architecture for change. It does it in two sessions. I'm going to continue covering this. The Compass NDA is coming. The DEA rescheduling decision will follow. The fda. The state level access picture is moving every month. Subscribe so you get the next episode when it drops.